Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $16.38.
Several equities research analysts have recently weighed in on PRQR shares. Zacks Investment Research downgraded shares of ProQR Therapeutics N.V. from a “hold” rating to a “sell” rating in a research report on Wednesday, April 19th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a report on Tuesday, June 20th.
ProQR Therapeutics N.V. (NASDAQ PRQR) traded down 1.06% during trading on Friday, reaching $4.65. 3,568 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $5.15 and a 200 day moving average price of $4.78. ProQR Therapeutics N.V. has a 1-year low of $3.65 and a 1-year high of $8.70. The stock’s market capitalization is $110.97 million.
ProQR Therapeutics N.V. (NASDAQ:PRQR) last released its earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.02. Equities research analysts expect that ProQR Therapeutics N.V. will post ($2.18) earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hikari Power Ltd acquired a new position in ProQR Therapeutics N.V. during the first quarter valued at approximately $121,000. Sphera Funds Management LTD. raised its position in ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 130,000 shares during the period. Finally, Artal Group S.A. raised its position in ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares during the period. 36.15% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was originally reported by BNB Daily and is owned by of BNB Daily. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/proqr-therapeutics-n-v-nasdaqprqr-receives-16-38-consensus-target-price-from-brokerages-updated-updated-updated.html.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.